Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Rapport Therapeutics (RAPP) Enterprise Value (2024 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Enterprise Value data on record, last reported at -$875.5 million in Q1 2026.

  • On a quarterly basis, Enterprise Value fell 1417.14% to -$875.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$875.5 million, a 1417.14% decrease, with the full-year FY2025 number at -$52.8 million, up 82.72% from a year prior.
  • Enterprise Value reached -$875.5 million in Q1 2026 per RAPP's latest filing, down from -$52.8 million in the prior quarter.
  • Over the last five years, Enterprise Value for RAPP hit a ceiling of -$39.4 million in Q3 2024 and a floor of -$875.5 million in Q1 2026.
  • A 4-year average of -$218.2 million and a median of -$128.9 million in 2023 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: skyrocketed 82.72% in 2025, then tumbled 1417.14% in 2026.
  • Tracing RAPP's Enterprise Value over 4 years: stood at -$147.5 million in 2023, then crashed by 107.0% to -$305.3 million in 2024, then surged by 82.72% to -$52.8 million in 2025, then tumbled by 1559.76% to -$875.5 million in 2026.
  • Business Quant data shows Enterprise Value for RAPP at -$875.5 million in Q1 2026, -$52.8 million in Q4 2025, and -$251.5 million in Q3 2025.